Ideaya Biosciences Inc (IDYA) Stock Price, Quote & News

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 443 6209

Website: www.ideayabio.com

Address:

5000 Shoreline Court, Suite 300, South San Francisco, United States

RonIsWrong Dec. 5 at 12:16 AM

$IDYA IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

0 · Reply

Iightning Dec. 4 at 10:06 PM

1ightning® Premium Options Alert (Actionable) Ticker: $IDYA Contract: Dec 19 $35C Entry: 2.38 Exit: 4.63 Return: +94.91% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HedgeAlerts Dec. 4 at 6:34 AM

Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $30.00 Put · DEC 19, 2025 Exp Entry Price: $0.50 - $1.00 Exit Price Target: $0.70 Profit Margin: +39% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Dec. 4 at 5:47 AM

1ightning® Premium Options Alert (Actionable) Ticker: $IDYA Contract: Dec 19 $30C Entry: 4.60 Exit: 6.97 Return: +51.51% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 4 at 3:34 AM

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA July 17, 2026 $40 Calls Scale in: $5.17- $6.33 Scale out: $20.12-$34.50 Profit Potential : 252% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Dpst2022 Dec. 3 at 10:18 AM

$IDYA $DNLI $SNDX $BCRX be weary of fake people who say one thing and do another. A lot of pumpers here and absolute fakeness like @CH_Expat who say things like this ticker is "undervalued, looking for 100% gains but will be just fine with 30% and this stock will turn around soon but then they just bail quickly.

5 · Reply

CH_Expat Dec. 3 at 7:29 AM

$IDYA is my only position right now. For my followers and as I like transparency: Possible entries after a correction are $SNDX (at 16 or lower), $DNLI (at 15 or lower), SLNO (40 or lower), SION (20s if ever) and ORKA (10s if ever). Other quality bios way too expensive right now. Small trades for BCRX and APLS under consideration.

0 · Reply

LiquidThetaOptions Dec. 2 at 12:55 AM

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA July 17, 2026 $30 Calls Scale in: $9.17- $11.21 Scale out: $35.67-$61.14 Profit Potential : 205% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Dec. 2 at 12:01 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $IDYA **Contract:** Dec 19 $35C **Entry:** 2.85 **Exit:** 3.70 **Return:** **+29.85% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

HedgeAlerts Dec. 1 at 9:26 PM

Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $30.00 Put · DEC 19, 2025 Exp Entry Price: $0.86 - $1.00 Exit Price Target: $1.74 Profit Margin: +102% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 6:00 AM EST - 3 days ago

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

Nov 28, 2025, 6:00 AM EST - 6 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2025, 4:58 PM EST - 9 days ago

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

Nov 24, 2025, 6:00 AM EST - 10 days ago

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

Nov 6, 2025, 7:06 PM EST - 4 weeks ago

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript

Nov 4, 2025, 6:00 AM EST - 4 weeks ago

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 27, 2025, 6:00 AM EDT - 5 weeks ago

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

Oct 20, 2025, 6:30 AM EDT - 6 weeks ago

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

Oct 20, 2025, 6:00 AM EDT - 6 weeks ago

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Sep 8, 2025, 6:41 PM EDT - 3 months ago

IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript)

Sep 8, 2025, 4:30 PM EDT - 3 months ago

IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst

Sep 8, 2025, 8:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

Sep 8, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

Sep 7, 2025, 12:00 PM EDT - 3 months ago

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Sep 4, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

Sep 3, 2025, 10:15 PM EDT - 3 months ago

IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Sep 2, 2025, 6:00 AM EDT - 3 months ago

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Aug 29, 2025, 2:00 PM EDT - 3 months ago

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Aug 25, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Aug 18, 2025, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

Aug 5, 2025, 4:23 PM EDT - 4 months ago

IDEAYA (IDYA) Q2 Net Loss Improves 27%

Aug 5, 2025, 8:43 AM EDT - 4 months ago

Ideaya Biosciences: Moving Into ADCs For Solid Tumors

Aug 5, 2025, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 24, 2025, 9:25 AM EDT - 4 months ago

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

Jul 23, 2025, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

Jul 22, 2025, 1:01 PM EDT - 4 months ago

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Jul 21, 2025, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

Jun 2, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

May 14, 2025, 5:30 PM EDT - 7 months ago

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849

May 6, 2025, 6:05 AM EDT - 7 months ago

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

Apr 28, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

Apr 16, 2025, 8:52 AM EDT - 8 months ago

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 14, 2025, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Apr 10, 2025, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Apr 2, 2025, 11:12 AM EDT - 8 months ago

Why Ideaya Biosciences Is Down Despite Many Positives

Apr 1, 2025, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

Mar 31, 2025, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Mar 26, 2025, 6:00 AM EDT - 9 months ago

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

Mar 3, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

Feb 13, 2025, 6:05 AM EST - 10 months ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 6:00 AM EST - 10 months ago

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

Feb 10, 2025, 4:36 PM EST - 10 months ago

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Feb 10, 2025, 6:00 AM EST - 10 months ago

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

Jan 27, 2025, 6:00 AM EST - 11 months ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Jan 12, 2025, 12:00 PM EST - 11 months ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

Dec 29, 2024, 6:00 AM EST - 1 year ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Dec 17, 2024, 6:00 AM EST - 1 year ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

RonIsWrong Dec. 5 at 12:16 AM

$IDYA IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

0 · Reply

Iightning Dec. 4 at 10:06 PM

1ightning® Premium Options Alert (Actionable) Ticker: $IDYA Contract: Dec 19 $35C Entry: 2.38 Exit: 4.63 Return: +94.91% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HedgeAlerts Dec. 4 at 6:34 AM

0 · Reply

Iightning Dec. 4 at 5:47 AM

1ightning® Premium Options Alert (Actionable) Ticker: $IDYA Contract: Dec 19 $30C Entry: 4.60 Exit: 6.97 Return: +51.51% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 4 at 3:34 AM

0 · Reply

Dpst2022 Dec. 3 at 10:18 AM

5 · Reply

CH_Expat Dec. 3 at 7:29 AM

0 · Reply

LiquidThetaOptions Dec. 2 at 12:55 AM

0 · Reply

Iightning Dec. 2 at 12:01 AM

0 · Reply

HedgeAlerts Dec. 1 at 9:26 PM

0 · Reply

CH_Expat Dec. 1 at 6:39 PM

$IDYA More good news. Did they ever mess up anything? Full trust in this management.

1 · Reply

notreload_ai Dec. 1 at 11:32 AM

$IDYA receives FDA clearance for IDE034, a first-in-class dual-target cancer therapy aimed at lung, colorectal, and head and neck tumors. https://notreload.xyz/ideaya-wins-fda-nod-for-ide034-dual-target-cancer-therapy/

0 · Reply

RonIsWrong Nov. 27 at 3:08 AM

$IDYA this sleeper's been steady

1 · Reply

CH_Expat Nov. 26 at 8:29 PM

$IDYA Up 92% in six months, five retailers, three bots, no postings, no pump, no bash, no drama. Hope it stays like this until the end.

1 · Reply

Iightning Nov. 26 at 2:52 AM

1ightning® Options Trade Alert (Actionable) | Buy $IDYA Dec 19 $35 Call | Enter: $2.58 Exit: $4.68 | Profit: 81.14% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 26 at 1:42 AM

Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $35.00 Put · DEC 19, 2025 Exp Entry Price: $3.00 - $4.90 Exit Price Target: $4.92 Profit Margin: +64% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

CH_Expat Nov. 25 at 7:02 PM

$IDYA To be clear: I will not sell my shares here. I am up with two years of net salary. No intention. Monster in the making. All lights green, 2026 will be the year of IDYA.

1 · Reply

CH_Expat Nov. 25 at 2:58 PM

$IDYA @Okadarlan You csn short it now. You are not afraid of Karma or cancer, so you can go for it as you said. We are at 35.

0 · Reply

Iightning Nov. 25 at 12:57 PM

1ightning® Options Trade Alert (Actionable) | Buy $IDYA Dec 19 $35 Call | Enter: $2.58 Exit: $4.68 | Profit: 81.14% ROI | https://1ightning.com

0 · Reply

LiquidThetaOptions Nov. 25 at 2:05 AM

💎 LiquidTheta® Live Actionable Trade Asset: $IDYA Contracts: $IDYA July 17, 2026 $30 Calls Scale in: $9.15- $11.18 Scale out: $35.58-$60.99 Profit Potential : 434% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Nov. 25 at 1:52 AM

1ightning® Options Trade Alert (Actionable) | Buy $IDYA Dec 19 $35 Call | Enter: $2.58 Exit: $4.68 | Profit: 81.14% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 25 at 1:43 AM

Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $30.00 Put · DEC 19, 2025 Exp Entry Price: $0.86 - $1.50 Exit Price Target: $1.43 Profit Margin: +66% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Market Cap	3.01B
Revenue (ttm)	7.00M
Net Income (ttm)	-274.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,921.14%
Debt to Equity Ratio	0.00

Volume	1,474,600
Avg Vol	1,139,340
Day's Range	N/A - N/A
Shares Out	87.67M
Stochastic %K	85%
Beta	0.04
Analysts	Strong Sell
Price Target	$48.94